Moving Forward: Side Effects, Recovery, and Monitoring
At a Glance
After anal cancer chemoradiation, side effects may peak near the end of treatment and for several weeks afterward, while bowel, urinary, and sexual changes can persist. Report fever or severe symptoms promptly and follow a personalized surveillance plan.
The completion of chemoradiation is a major milestone, but it is often the beginning of a new phase: managing the acute side effects of treatment and transitioning into long-term survivorship. While the goal is to cure the cancer, the intensity of the treatment means that your body will need time to heal, and some changes may require ongoing management.
Managing Acute Side Effects
During your 5 to 6 weeks of treatment, you will likely experience side effects that peak toward the end of therapy and for a few weeks afterward. Managing these effectively is vital to ensure you complete your treatment safely [1].
- Radiation Dermatitis: This is a significant skin reaction in the groin and anal area. In studies using modern IMRT (Intensity-Modulated Radiation Therapy), over 85% of patients experienced moderate to severe skin irritation [2]. This can feel like a severe sunburn and may involve peeling or blistering.
- Neutropenia: The chemotherapy (specifically Mitomycin C and 5-FU) can temporarily lower your white blood cell count (neutropenia). Rates of severe neutropenia vary, but some studies have seen it in 20% to 70% of patients depending on the specific drug combination [3][4]. Your team will monitor your blood weekly to ensure it is safe to continue. Critical Safety Warning: If you develop a fever (commonly defined as 100.4°F/38.0°C or higher, but confirm your team’s threshold), severe chills, or new infection symptoms, you must contact your oncology team or go to the ER immediately. Do not wait for your next weekly blood test.
- Acute Diarrhea and Pain: Inflammation of the lining of the anus and rectum (proctitis) can cause urgent bowel movements, diarrhea, and significant pain [5][6].
Tip: Use only the creams and washes recommended by your radiation team. While avoiding unnecessary breaks is critical, never push through dangerous side effects; report severe skin breakdown, inability to urinate, or uncontrolled diarrhea promptly.
Long-Term Survivorship and Functional Health
Survivorship in anal cancer often involves managing “late effects”—symptoms that appear months or even years after treatment ends. Because radiation affects the entire pelvic area, several systems may be impacted:
Bowel and Urinary Function
Late bowel issues are common, with some form of dysfunction reported in up to 78% of survivors [7]. This may include:
- Fecal Incontinence: Up to 44% of patients report difficulty controlling bowel movements or experiencing urgency [8].
- Urinary Changes: About 21% of survivors report long-term urinary incontinence or frequency [9].
- Management: These percentages vary by study, and referrals to gastroenterology or continence care can help manage these symptoms. Pelvic floor physical therapy is a highly effective, evidence-based intervention that helps retrain the muscles of the pelvis [10].
Sexual Health
Sexual dysfunction is one of the most persistent challenges after anal cancer treatment, affecting a high percentage of both men and women [7].
- Vaginal Health: Radiation can cause the vaginal tissues to become thin, dry, and less elastic (vaginal stenosis). In one study, 80% of sexually active women reported significant sexual dysfunction after treatment [11].
- Actionable Step: The regular use of a vaginal dilator and water-based lubricants can help maintain vaginal health and reduce pain during future exams or intercourse [11][12]. Important: Dilators should generally be introduced only after acute radiation injury has healed and according to your team’s instructions. Do not use them during active severe mucositis, if you have open sores, or significant bleeding.
- Men’s Health: Men may experience erectile dysfunction or changes in sensation [7].
Your Surveillance Schedule
Once treatment is complete, you will enter a period of close monitoring to ensure the cancer does not return. Most recurrences occur within the first 3 years, though follow-up typically continues for at least 5 years [13].
Typical Follow-Up Timeline:
- Clinical Exams: Clinical examination with Digital Rectal Exam (DRE) and groin-node assessment is often performed every 3–6 months for five years [14][15].
- Anoscopy: Visual inspection of the anal canal may be performed at different intervals determined by your specialist.
- Imaging: Imaging is stage- and symptom-dependent; routine CT or MRI for all survivors is not standard [16].
It is normal to feel “scanxiety”—the anxiety that builds before a follow-up appointment. Knowing your schedule and having a clear plan for your functional recovery can help you regain a sense of control over your health [7]. Keep a symptom diary so you can accurately discuss changes, and remember that post-radiation inflammation can sometimes mimic recurrence on scans; a concerning symptom does not automatically mean the cancer has returned.
Common questions in this guide
When should I call my cancer team after anal cancer treatment?
How can late bowel or urinary problems after anal cancer treatment be managed?
When is it safe to use a vaginal dilator after anal cancer radiation?
How often are follow-up visits needed after anal cancer treatment?
Can post-radiation inflammation look like anal cancer recurrence?
One line in your results can change your plan.
Whether CT or MRI imaging is needed after treatment depends on stage and symptoms, a question for your oncologist. We check your results against the latest research to help you prepare for what’s next.
Get notified when new evidence is published on anus cancer.
We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.
References
References (16)
- 1
Intensity-modulated Radiotherapy for Anal Cancer: Dose-Volume Relationship of Acute Gastrointestinal Toxicity and Disease Outcomes.
Ng M, Ho H, Skelton J, et al.
Clinical oncology (Royal College of Radiologists (Great Britain)) 2018; (30(10)):634-641 doi:10.1016/j.clon.2018.07.020.
PMID: 30049649 - 2
Evaluation of dosimetric predictors of toxicity after IMRT with concurrent chemotherapy for anal cancer.
Lukovic J, Hosni A, Liu A, et al.
Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology 2023; (178()):109429 doi:10.1016/j.radonc.2022.11.018.
PMID: 36455685 - 3
Irradiation of anatomically defined pelvic subsites and acute hematologic toxicity in anal cancer patients undergoing chemoradiation.
Rose B, Mitra D, Hong TS, et al.
Practical radiation oncology 2017; (7(5)):e291-e297 doi:10.1016/j.prro.2017.03.008.
PMID: 28462895 - 4
Capecitabine With Mitomycin Reduces Acute Hematologic Toxicity and Treatment Delays in Patients Undergoing Definitive Chemoradiation Using Intensity Modulated Radiation Therapy for Anal Cancer.
Goodman KA, Julie D, Cercek A, et al.
International journal of radiation oncology, biology, physics 2017; (98(5)):1087-1095 doi:10.1016/j.ijrobp.2017.03.022.
PMID: 28721892 - 5
Intensity modulated radiotherapy in anal canal squamous cell carcinoma: Implementation and outcomes.
Das A, Arunsingh M, Bhattacharyya T, et al.
Journal of cancer research and therapeutics 2021; (17(4)):975-981 doi:10.4103/jcrt.JCRT_212_19.
PMID: 34528551 - 6
Comparison of definitive chemoradiation with 5-fluorouracil versus capecitabine in anal cancer.
Pumpalova Y, Kozak MM, von Eyben R, et al.
Journal of gastrointestinal oncology 2019; (10(4)):605-615 doi:10.21037/jgo.2019.02.17.
PMID: 31392040 - 7
Management of late adverse effects after chemoradiation for anal cancer.
Haas S, Mikkelsen AH, Kronborg C, et al.
Acta oncologica (Stockholm, Sweden) 2021; (60(12)):1688-1701 doi:10.1080/0284186X.2021.1983208.
PMID: 34845967 - 8
Late gastrointestinal toxicity after radiotherapy for anal cancer: a systematic literature review.
Pan YB, Maeda Y, Wilson A, et al.
Acta oncologica (Stockholm, Sweden) 2018; (57(11)):1427-1437 doi:10.1080/0284186X.2018.1503713.
PMID: 30264638 - 9
Long-Term Patient-Reported Quality of Life of Anal Cancer Survivors Treated With Intensity Modulated Radiation Therapy and Concurrent Chemotherapy: Results From a Prospective Phase II Trial.
Joseph K, Balushi MA, Ghosh S, et al.
International journal of radiation oncology, biology, physics 2023; (117(2)):434-445 doi:10.1016/j.ijrobp.2023.04.023.
PMID: 37148982 - 10
Patients' perspective in anal cancer.
Manfrida S, Dinapoli L, De Luca V, et al.
ESMO gastrointestinal oncology 2026; (13(Pt A)):100203 doi:10.1016/j.esmogo.2025.100203.
PMID: 42582940 - 11
Daily Vaginal Dilator Use During Radiation for Women With Squamous Cell Carcinoma of the Anus: Vaginal Wall Dosimetry and Patient-Reported Sexual Function.
Arzola A, Chang E, Rooney MK, et al.
Practical radiation oncology 2024; (14(2)):e105-e116 doi:10.1016/j.prro.2023.10.002.
PMID: 37898354 - 12
Enhancing quality of life: addressing vulvovaginal atrophy and urinary tract symptoms.
Hirschberg AL
Climacteric : the journal of the International Menopause Society 2025; (28(4)):400-407 doi:10.1080/13697137.2025.2514029.
PMID: 40531325 - 13
Pulmonary Metastasis of Anal Squamous Cell Carcinoma Nine Years Following Treatment.
Madani MS, Deogaonkar A, Naum AS, et al.
Cureus 2025; (17(12)):e98238 doi:10.7759/cureus.98238.
PMID: 41480477 - 14
Anal Carcinoma, Version 2.2018, NCCN Clinical Practice Guidelines in Oncology.
Benson AB, Venook AP, Al-Hawary MM, et al.
Journal of the National Comprehensive Cancer Network : JNCCN 2018; (16(7)):852-871 doi:10.6004/jnccn.2018.0060.
PMID: 30006428 - 15
Introducing the eighth edition of the tumor-node-metastasis classification as relevant to colorectal cancer, anal cancer and appendiceal cancer: a comparison study with the seventh edition of the tumor-node-metastasis and the Japanese Classification of Colorectal, Appendiceal, and Anal Carcinoma.
Shida D, Kanemitsu Y, Hamaguchi T, Shimada Y
Japanese journal of clinical oncology 2019; (49(4)):321-328 doi:10.1093/jjco/hyy198.
PMID: 30608547 - 16
An Updated Review on Imaging and Staging of Anal Cancer-Not Just Rectal Cancer.
Congedo A, Mallardi D, Danti G, et al.
Tomography (Ann Arbor, Mich.) 2023; (9(5)):1694-1710 doi:10.3390/tomography9050135.
PMID: 37736988
This page is for informational purposes only and does not replace medical advice. Contact your oncology team promptly about fever, severe symptoms, or new concerns after anal cancer treatment.